Intervention not reported
Serious adverse events · people at risk for the development of type 2 diabetes mellitus
1 finding from 1 review
Intervention not reported
Serious adverse events · people at risk for the development of type 2 diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with multifocal motor neuropathy
1 finding from 1 review
Serious adverse events · Children and adults with blood smear positive P. vivax malaria1
1 finding from 1 review
Intervention not reported
Serious adverse events · People with P. vivax malaria1
1 finding from 1 review
Intervention not reported
Serious adverse events · People with P. vivax malaria1
1 finding from 1 review
Serious adverse events · People with P. vivax malaria1
1 finding from 1 review
Serious adverse events · People with P. vivax malaria1
1 finding from 1 review
Serious adverse events · High‐risk HIV‐uninfected individuals (including serodiscordant couples, men who have sex with men and sex workers)
TDF+ FTC showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · High‐risk individuals (including serodiscordant couples, men who have sex with men and sex workers)
TDF showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events (during intervention)Â · children/adolescents with post‐traumatic stress and related depressive/anxiety symptoms
1 finding from 1 review
Adverse events considered non‐serious · children with portal hypertension and large oesophageal varices, without previous gastrointestinal bleeding or beta‐blocker treatment
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (Grade 3 or 4) · Previous treated and treatment‐naïve (54%) metastatic renal cell carcinoma (clear cell type)
Pazopanib leads to higher serious adverse events (Grade 3 or 4) compared with placebo (targeted agent versus placebo) (high certainty).
1 finding from 1 review
Intervention not reported
Reported adverse events · people with stroke or transient ischaemic attack
The intervention showed no clear difference in reported adverse events (low certainty).
1 finding from 1 review
Adverse effects ‐ Stroke · cognitively healthy people in late life
Other NSAIDs showed no clear difference in adverse events – stroke compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events or adverse events · individuals dependent on illicit opiates
1 finding from 1 review
Adverse events ‐ abdominal overdistention · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
It is very uncertain whether summary of findings table ‐ High flow nasal cannula (HFNC) changes adverse events ‐ abdominal overdistention compared with continuous positive airway pressure (CPAP) (very low certainty).
1 finding from 1 review
Any other adverse events · women undergoing assisted reproduction
It is very uncertain whether dopamine agonist plus co‐intervention changes any other adverse events compared with co‐intervention (very low certainty).
1 finding from 1 review
Any other adverse events · women undergoing assisted reproduction
1 finding from 1 review
Any other adverse events · women undergoing assisted reproduction
It is very uncertain whether dopamine agonist changes any other adverse events compared with placebo/no intervention (very low certainty).
1 finding from 1 review